Shanghai Pharmaceuticals Holding Co., Ltd
Hong Kong Stock ExchangeTotal Valuation
Shanghai Pharmaceuticals Holding Co., Ltd carries a market capitalization of 69.61B, placing it among publicly traded companies globally. Its enterprise value stands at 64.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 69.61B |
| Enterprise Value | 64.56B |
Share Statistics
Shanghai Pharmaceuticals Holding Co., Ltd currently has 3.71B shares outstanding.
| Shares Outstanding | 3.71B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shanghai Pharmaceuticals Holding Co., Ltd trades at a trailing price-to-earnings ratio of 7.40. The price-to-sales ratio is 0.18, and the price-to-book ratio stands at 0.83.
| PE Ratio | 7.40 |
| PS Ratio | 0.18 |
| PB Ratio | 0.83 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | 21.12 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shanghai Pharmaceuticals Holding Co., Ltd trades at an EV/EBITDA multiple of 8.64 and an EV/FCF ratio of 21.97. The EV/Sales ratio of 0.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.64 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.30 |
| EV / EBITDA | 8.64 |
| EV / EBIT | 8.64 |
| EV / FCF | 21.97 |
Financial Position
Shanghai Pharmaceuticals Holding Co., Ltd maintains a current ratio of 1.34, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 58.59, indicating elevated leverage, while an interest coverage ratio of 4.70 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.34 |
| Quick Ratio | 0.30 |
| Debt / Equity | 58.59 |
| Debt / EBITDA | 7.17 |
| Interest Coverage | 4.70 |
Financial Efficiency
Shanghai Pharmaceuticals Holding Co., Ltd posts a return on equity of 11.71 and a return on invested capital of 3.76.
| Return on Equity (ROE) | 11.71 |
| Return on Assets (ROA) | 2.22 |
| Return on Invested Capital (ROIC) | 3.76 |
| Return on Capital Employed (ROCE) | 4.71 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.80 |
Taxes
Over the trailing twelve months, Shanghai Pharmaceuticals Holding Co., Ltd has paid 2.42B in income taxes, reflecting an effective tax rate of 28.07.
| Income Tax | 2.42B |
| Effective Tax Rate | 28.07 |
Stock Price Statistics
Shanghai Pharmaceuticals Holding Co., Ltd's stock has gained approximately 1.0101% over the past 52 weeks. The 50-day moving average sits at 11.78, while the 200-day moving average is 11.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | 1.0101% |
| 50-Day Moving Average | 11.78 |
| 200-Day Moving Average | 11.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shanghai Pharmaceuticals Holding Co., Ltd generated 214.60B in revenue and converted that into 5.12B in net income, yielding earnings per share of 1.66. EBITDA reached 7.47B, while operating income came in at 7.47B.
| Revenue | 214.60B |
| Gross Profit | 23.77B |
| Operating Income | 7.47B |
| Pretax Income | 8.61B |
| Net Income | 5.12B |
| EBITDA | 7.47B |
| EBIT | 7.47B |
| Earnings Per Share (EPS) | 1.66 |
Balance Sheet
Shanghai Pharmaceuticals Holding Co., Ltd holds 41.12B in cash and equivalents against 53.59B in total debt, resulting in a net debt position of 18.75B. Total book value stands at 45.85B, with working capital of 46.33B providing operational flexibility.
| Cash & Cash Equivalents | 41.12B |
| Total Debt | 53.59B |
| Net Debt | 18.75B |
| Equity (Book Value) | 45.85B |
| Book Value Per Share | 12.29 |
| Working Capital | 46.33B |
Cash Flow
After subtracting -1.80B in capital expenditures, free cash flow totaled -1.80B - equivalent to -0.48 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -1.80B |
| Free Cash Flow | -1.80B |
| FCF Per Share | -0.48 |
Margins
Shanghai Pharmaceuticals Holding Co., Ltd operates with a gross margin of 11.07, reflecting its pricing power and cost economics. The operating margin of 3.48 and net profit margin of 2.39 provide insight into operational efficiency.
| Gross Margin | 11.07 |
| Operating Margin | 3.48 |
| Pretax Margin | 4.01 |
| Profit Margin | 2.39 |
| EBITDA Margin | 3.48 |
Dividends & Yields
The company's payout ratio of 21.39 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.42 |
| Dividend Yield | N/A |
| Payout Ratio | 21.39 |
| Shareholder Yield | 13.34 |
| FCF Yield | 4.73 |
Scores
Shanghai Pharmaceuticals Holding Co., Ltd posts an Altman Z-Score of 1.81, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.81 |